The unlikely inventor and the reluctant manufacturer - Coloplast's start-up story Custom Case Solution & Analysis

1. Evidence Brief

Financial Metrics

Initial production run: 1000 units ordered by Aage Louis-Hansen after initial hesitation.
Market demand: 1000 units sold out immediately upon release.
Order backlog: 60000 units requested within the first year of production.
Revenue source: Transition from general plastic packaging (Dansk Plastic Emballage) to specialized medical devices.

Operational Facts

Product design: A disposable ostomy bag made of thin plastic film with an adhesive ring.
Manufacturing transition: Shift from manual prototype assembly by Elise Sorensen to industrial plastic welding at Dansk Plastic Emballage.
Geography: Based in Denmark, 1954-1957.
Distribution channel: Direct sales to hospitals and pharmacies following successful nurse-led trials.

Stakeholder Positions

Elise Sorensen: Nurse and inventor. Motivated by her sister Thora’s social isolation due to leaky ostomy appliances. Held the patent for the first adhesive ostomy bag.
Aage Louis-Hansen: Owner of Dansk Plastic Emballage. Initially skeptical, preferring stable industrial packaging over unproven medical niches.
Johanne Louis-Hansen: Aage’s wife and a trained nurse. Acted as the primary advocate for the invention, bridging the gap between clinical need and manufacturing capability.
Thora Sorensen: The patient whose personal struggle provided the impetus for the invention and the primary user persona.

Information Gaps

Unit economics: The case lacks specific data on the cost per unit versus the retail price in 1954.
Patent details: Specific duration and international filing status of the original patent are not fully detailed.
Competitor response: Limited information on how existing rubber-bag manufacturers reacted to the disposable threat.

2. Strategic Analysis

Core Strategic Question

Can a small-scale plastic manufacturer successfully pivot its business model to dominate a specialized medical niche by commercializing a user-led innovation?

Structural Analysis

The ostomy market in 1954 was defined by high friction and low dignity. Using the Jobs to be Done lens, the existing solution (reusable rubber bags) failed the primary job: allowing patients to return to social life without fear of leakage or odor. Elise Sorensen’s invention addressed the emotional and social dimensions of the job, not just the functional one.

From a Porter’s Five Forces perspective, the threat of substitutes was low because the current substitute was socially unacceptable. The bargaining power of suppliers was negligible as plastic film was a commodity. The primary barrier to entry was the patent and the specialized knowledge required to make an adhesive that was both skin-friendly and leak-proof.

Strategic Options

Option	Rationale	Trade-offs
Found a Dedicated Entity (Coloplast)	Captures full value chain and builds a brand around medical expertise.	High capital requirement and diversion from the core packaging business.
License Technology	Immediate cash flow with zero manufacturing risk.	Loss of control over quality and long-term margin potential.
Contract Manufacturing	Aage produces the bags for Elise without taking ownership of the brand.	Limits Aage’s upside while leaving Elise with the burden of marketing.

Preliminary Recommendation

Aage and Elise should form a new, specialized corporation. The immediate sell-out of the first 1000 units proves a massive product-market fit. The packaging business provides the technical foundation, but the medical device market requires a different regulatory and sales mindset. Founding Coloplast allows for the focused development of this high-margin niche.

3. Implementation Roadmap

Critical Path

Month 1-2: Formalize the partnership agreement between Elise Sorensen and Aage Louis-Hansen, securing the patent rights for the new entity.
Month 3-4: Scale production capacity by investing in specialized plastic welding machinery tailored for medical-grade adhesives.
Month 5-6: Establish a clinical sales force, utilizing Johanne Louis-Hansen’s professional network to gain hospital endorsements.
Month 7-12: Expand distribution to international markets, starting with neighboring European countries facing similar healthcare challenges.

Key Constraints

Manufacturing Precision: The transition from 1000 to 60000 units risks quality variability, specifically in the adhesive-to-plastic bond strength.
Regulatory Compliance: Moving from industrial plastic to medical devices requires adherence to emerging health standards and sterilization protocols.
Founder Friction: Balancing Elise’s clinical vision with Aage’s manufacturing pragmatism is essential for long-term stability.

Risk-Adjusted Implementation Strategy

The strategy prioritizes production stability over aggressive marketing. Because the demand is organic and overwhelming, the primary risk is a product recall due to skin irritation or leakage. Implementation will include a phased rollout where each new batch undergoes rigorous stress testing before hospital delivery. Contingency plans include keeping the original packaging business operational to provide a financial safety net during the medical unit’s growth phase.

4. Executive Review and BLUF

BLUF

The decision to manufacture the Sorensen ostomy bag is an asymmetric opportunity. The immediate 60-fold increase in demand confirms a profound market void. Success depends on transitioning from a generalist plastic shop to a specialized medical manufacturer. The priority is securing the patent and scaling production to meet the 60000-unit backlog before competitors replicate the adhesive mechanism. Proceed with founding the dedicated medical entity immediately.

Dangerous Assumption

The analysis assumes that Aage Louis-Hansen’s current manufacturing setup can scale to medical-grade standards without significant capital expenditure or specialized clean-room environments. If the industrial plastic welding process introduces contaminants, the medical risk could bankrupt the parent company.

Unaddressed Risks

Patent Enforceability: High probability. If the patent is narrow, competitors may bypass it by using slightly different adhesive compositions, eroding the first-mover advantage.
Supply Chain Concentration: Moderate probability. Reliance on a specific adhesive supplier could create a bottleneck as production scales to tens of thousands of units.

Unconsidered Alternative

The team did not consider a global licensing play with an established pharmaceutical giant. While this reduces long-term upside, it would have provided instant global distribution and shifted all manufacturing and regulatory risks to a partner better equipped to handle them in 1954.